Moreover, the 36-month beta value for SNOA is 1.37. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SNOA is 1.32M and currently, short sellers hold a 8.07% of that float. On October 11, 2024, SNOA’s average trading volume was 194.54K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
SNOA) stock’s latest price update
The stock of Sonoma Pharmaceuticals Inc. (NASDAQ: SNOA) has increased by 4.90 when compared to last closing price of 2.86.Despite this, the company has seen a gain of 5.26% in its stock price over the last five trading days. accesswire.com reported 2024-09-19 that BOULDER, CO / ACCESSWIRE / September 19, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it received a formal determination letter from Nasdaq notifying Sonoma that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market and the matter is now closed. As previously reported, On September 22, 2023, Sonoma received a letter from Nasdaq indicating that it did not comply with the $1.00 minimum closing bid price requirement for its common stock for continued listing on the Nasdaq Capital Market.
SNOA’s Market Performance
SNOA’s stock has risen by 5.26% in the past week, with a monthly drop of -8.26% and a quarterly drop of -59.62%. The volatility ratio for the week is 9.47% while the volatility levels for the last 30 days are 15.40% for Sonoma Pharmaceuticals Inc. The simple moving average for the past 20 days is -9.57% for SNOA’s stock, with a -23.62% simple moving average for the past 200 days.
SNOA Trading at -25.00% from the 50-Day Moving Average
After a stumble in the market that brought SNOA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.25% of loss for the given period.
Volatility was left at 15.40%, however, over the last 30 days, the volatility rate increased by 9.47%, as shares sank -5.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -58.90% lower at present.
During the last 5 trading sessions, SNOA rose by +5.26%, which changed the moving average for the period of 200-days by -12.28% in comparison to the 20-day moving average, which settled at $3.32. In addition, Sonoma Pharmaceuticals Inc. saw -16.85% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SNOA
Current profitability levels for the company are sitting at:
- -0.36 for the present operating margin
- 0.38 for the gross margin
The net margin for Sonoma Pharmaceuticals Inc. stands at -0.36. The total capital return value is set at -0.47. Equity return is now at value -74.65, with -30.85 for asset returns.
Based on Sonoma Pharmaceuticals Inc. (SNOA), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -7.37.
Currently, EBITDA for the company is -4.53 million with net debt to EBITDA at 0.49. When we switch over and look at the enterprise to sales, we see a ratio of 0.15. The receivables turnover for the company is 3.91for trailing twelve months and the total asset turnover is 0.93. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.12.
Conclusion
To wrap up, the performance of Sonoma Pharmaceuticals Inc. (SNOA) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
